TNFerade(TM) Phase III Data Presented at ASCO
TNFerade(TM) Phase III Data Presented at ASCO. ... data in locally advanced pancreatic cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase
...
http://www.prnewswire.com/news-releases/tnferadetm-phase-iii...
|
Google Finance: GenVec, Inc.
4 Oct 2009 ... The analysis concluded that TNFerade appeared to be safe and well- tolerated. ... alone in patients with locally advanced pancreatic cancer. The next ... the
K-M Curves and say they'll be presented at ASCO. ...
http://www.google.com/group/google.finance.665511/t/fda211e9...
|
Borderline Resectable Pancreatic Cancer: On the Edge of Survival ...
Gene Therapy for Locally Advanced Pancreatic Cancer: Do neoadjuvant treatment ... The TNF-α gene in TNFerade is linked to a promoter element from the early
.... pancreatic cancer. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. ...
http://www.medscape.com/viewarticle/581214_8...
|
ASCO 40th Annual Meeting
16:21 ET, Scientific Data Presented at ASCO Annual Meeting Demonstrating Synergy of ... Survival Data for TNFerade(TM) in Phase II Pancreatic Cancer Study ...
http://www.prnewswire.com/gh/cnoc/comp/638289.html...
|
Borderline Resectable Pancreatic Cancer: On the Edge of Survival ...
Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Past, Present, ... pancreatic cancer. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. ...
TNFerade biologic, an adenovector with a radiation-inducible promoter, ...
http://www.medscape.com/viewarticle/581214_3...
|
Pancreatic Cancer - BioSpace offers Pharmaceutical, Biotechnology ...
Pancreatic Cancer: Discovery Offers Potential New Treatment, ..... Update In Phase II/III Clinical Trial Of TNFerade(TM) In Locally Advanced Pancreatic
Cancer; .... Avantogen Limited And Innovate Oncology, Inc. Announce ASCO
Abstracts ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...
|
Borderline Resectable Pancreatic Cancer: On the Edge of Survival ...
Metastatic pancreatic cancer treated with GTX chemotherapy. ..... pancreatic cancer. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. ... randomized
controlled clinical trial using TNFerade combined with chemoradiation in
patients ...
http://www.medscape.com/viewarticle/581214_6...
|
Cancer of the Pancreas: Are We Making Progress? A Review of ...
15% of patients who present with pancreatic cancer are ..... cancer. 02020. Randomized phase II study of TNFerade biologic with ... 2005 ASCO Annual Meeting
Proceedings. 2005;23(16S June 1 suppl): LBA4009. Abstract. ...
http://www.moffitt.org/CCJRoot/v15n4/pdf/308.pdf...
|
Borderline Resectable Pancreatic Cancer: On the Edge of Survival ...
In a series of 82 patients with potentially resectable pancreatic cancer who were ..... pancreatic cancer. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings
. ... TNFerade biologic, an adenovector with a radiation-inducible promoter, ...
http://www.medscape.com/viewarticle/581214_2...
|
Borderline Resectable Pancreatic Cancer: On the Edge of Survival
controlled multicenter phase II/III trial of TNFerade, des- ..... sectable pancreatic cancer. J Clin Oncol. 2005 ASCO Annual Meeting Pro- ceedings. ...
http://www.moffitt.org/moffittapps/ccj/v15n4/pdf/295.pdf...
|
